Zoetis Completes Acquisition of Basepaws, an Innovative Leader in Petcare Genetics, to Strengthen its Portfolio of Precision Animal Health Solutions
June 22 2022 - 8:30AM
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced the completion of its
acquisition of Basepaws, a privately held petcare genetics company,
which provides pet owners with genetic tests, analytics and early
health risk assessments. The genetic insights from Basepaws help
pet owners and veterinarians understand an individual pet’s risk
for disease and can lead to more meaningful engagements and
increased likelihood of early detection and treatment of disease.
The acquisition was first announced on June 7th, and financial
terms of the transaction were not disclosed.
“When we first met Basepaws CEO Anna Skaya and the team, we were
immediately drawn to their passion for pets and the role that
genetic testing and data analytics can have in advancing animal
care – a purpose that drives us every day,” said Zoetis CEO Kristin
Peck. “The addition of Basepaws will enhance our portfolio in the
precision animal health space and inform our future pipeline of
petcare innovations. Working together, we can continue to provide
veterinarians and pet owners with more comprehensive ways to
proactively manage the health, wellness and quality of care for
their animals.”
About Basepaws
Basepaws is a petcare genetics company that builds early
detection health risk tests based on genetic and microbiome data.
Basepaws is committed to companion animal health research, and it
has the world’s first at-home genetic testing platform for cats.
Founded in 2017 by Anna Skaya, the company is based in Los Angeles,
CA. For more information, visit www.basepaws.com.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After 70 years innovating ways to
predict, prevent, detect, and treat animal illness, Zoetis
continues to stand by those raising and caring for animals
worldwide – from livestock farmers to veterinarians and pet owners.
The company’s leading portfolio and pipeline of medicines,
vaccines, diagnostics and technologies make a difference in over
100 countries. A Fortune 500 company, Zoetis generated revenue of
$7.8 billion in 2021 with approximately 12,100 employees. For more
information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to: expectations regarding
the performance of acquired companies and our ability to integrate
new businesses; expectations regarding the financial impact of
acquisitions; business plans or prospects, future operating or
financial performance, future guidance, future operating models;
R&D costs; timing and likelihood of success; expectations
regarding products, product approvals or products under
development, expected timing of product launches; the impact of the
coronavirus (COVID-19) global pandemic and any recovery therefrom
on our business, supply chain, customers and employees; future use
of cash, dividend payments and share repurchases; tax rate and tax
regimes and any changes thereto; and other future events. These
statements are not guarantees of future performance or actions.
Forward-looking statements are subject to risks and uncertainties.
If one or more of these risks or uncertainties materialize, or if
management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.
A further list and description of risks, uncertainties and other
matters can be found in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, including in the sections
thereof captioned “Forward-Looking Statements and Factors That May
Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. Such risks and uncertainties may be amplified by the COVID-19
global pandemic and its potential impact on the global economy and
our business. These filings and subsequent filings are available
online at www.sec.gov, www.zoetis.com, or on request from
Zoetis.
ZTS-COR ZTS-IR ZTS-FIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621006057/en/
Media Contacts: Bill Price
1-973-443-2742 (o) William.price@zoetis.com Kristen Seely
1-973-443-2777 (o) Kristen.seely@zoetis.com Anna Skaya
1-949-426-9229 (o) anna@basepaws.com Investor
Contact: Steve Frank 1-973-822-7141
steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024